XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 28, 2024
Sep. 30, 2023
Sep. 28, 2024
Sep. 30, 2023
Revenues:        
Total revenues $ 13,319,608 $ 10,598,497 $ 35,688,672 $ 31,816,544
Expenses:        
Cost of product revenues 8,316,904 5,437,953 25,543,806 17,759,117
Research and development 2,596,649 3,089,935 6,537,065 8,534,411
Selling, general and administration 5,206,880 4,798,598 19,706,613 15,912,848
Litigation damages 24,800,000
Total expenses 16,120,433 13,326,486 76,587,484 42,206,376
Loss from operations (2,800,825) (2,727,989) (40,898,812) (10,389,832)
Other (expense) income        
Interest income 220,017 299,506 619,534 623,971
Other income 6,176 31,608 25,000 104,403
Loss on impairment of investments, net (903,609) (1,637,895) (3,327,347)
Foreign currency transaction gains (losses) 142,899 (14,438) 86,618 (153,442)
Total other (expense) income, net (534,517) 316,676 (906,743) (2,752,415)
Loss before provision for income taxes (3,335,342) (2,411,313) (41,805,555) (13,142,247)
Tax provision (125,000) (39,000) (125,000) (117,000)
Net loss $ (3,460,342) $ (2,450,313) $ (41,930,555) $ (13,259,247)
Net loss per share        
Basic $ (0.03) $ (0.02) $ (0.34) $ (0.12)
Diluted $ (0.03) $ (0.02) $ (0.34) $ (0.12)
Weighted average number of common shares outstanding        
Basic 124,318,056 110,360,814 121,944,597 108,436,146
Diluted 124,318,056 110,360,814 121,944,597 108,436,146
Net Product Revenues [Member]        
Revenues:        
Total revenues $ 10,922,470 $ 5,506,193 $ 31,001,866 $ 19,172,302
Research and Development Revenues [Member]        
Revenues:        
Total revenues 2,268,072 4,956,386 4,338,366 11,737,062
Other Revenues [Member]        
Revenues:        
Total revenues $ 129,066 $ 135,918 $ 348,440 $ 907,180